Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

While amyloid-targeting therapies continue to predominate in the Alzheimer’s disease (AD) drug development pipeline, there is increasing recognition that to effectively treat the disease it may be necessary to target other mechanisms and pathways as well. In December 2019, The EU/US CTAD Task Force...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Prev Alzheimers Dis
Autors principals: Gauthier, Serge, Aisen, P. S., Cummings, J., Detke, M. J., Longo, F. M., Raman, R., Sabbagh, M., Schneider, L., Tanzi, R., Tariot, P., Weiner, M., Touchon, J., Vellas, B.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
CTAD Task Force Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7223540/
https://ncbi.nlm.nih.gov/pubmed/32420298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14283/jpad.2020.18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars